[{"id":"538d8bf3-e272-434c-a377-1b2ea1e13ae7","acronym":"MATRIX EG","url":"https://clinicaltrials.gov/study/NCT00215644","created_at":"2021-01-18T00:43:52.032Z","updated_at":"2025-02-25T14:48:05.965Z","phase":"Phase 2","brief_title":"Matuzumab Treatment With Epirubicin, Cisplatin and Capecitabine (ECX) in Esophago-Gastric Cancer","source_id_and_acronym":"NCT00215644 - MATRIX EG","lead_sponsor":"Merck KGaA, Darmstadt, Germany","biomarkers":" EGFR","pipe":" | ","alterations":" EGFR expression","tags":["EGFR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EGFR expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cisplatin • capecitabine • epirubicin • matuzumab (EMD 72000)"],"overall_status":"Completed","enrollment":" Enrollment 72","initiation":"Initiation: 08/31/2005","start_date":" 08/31/2005","primary_txt":" Primary completion: 07/31/2008","primary_completion_date":" 07/31/2008","study_txt":" Completion: 08/31/2008","study_completion_date":" 08/31/2008","last_update_posted":"2018-11-02"},{"id":"f8a1a93a-a41c-4ee1-b47d-0b23575c2621","acronym":"EMD 72000-031","url":"https://clinicaltrials.gov/study/NCT00111839","created_at":"2021-01-18T00:22:02.899Z","updated_at":"2024-07-02T16:37:11.718Z","phase":"Phase 2","brief_title":"Effects of Matuzumab in Combination With Pemetrexed for the Treatment of Advanced Lung Cancer","source_id_and_acronym":"NCT00111839 - EMD 72000-031","lead_sponsor":"EMD Serono","biomarkers":" EGFR","pipe":" | ","alterations":" EGFR expression","tags":["EGFR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EGFR expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e gemcitabine • pemetrexed • vinorelbine tartrate • matuzumab (EMD 72000)"],"overall_status":"Completed","enrollment":" Enrollment 150","initiation":"Initiation: 05/31/2005","start_date":" 05/31/2005","primary_txt":" Primary completion: 07/31/2007","primary_completion_date":" 07/31/2007","study_txt":" Completion: 03/31/2009","study_completion_date":" 03/31/2009","last_update_posted":"2018-04-06"},{"id":"0b833bde-f248-4651-b174-8e2d0532e34c","acronym":"EMD 72000-030","url":"https://clinicaltrials.gov/study/NCT00073541","created_at":"2021-01-18T00:11:33.406Z","updated_at":"2024-07-02T16:37:26.352Z","phase":"Phase 2","brief_title":"A Study of the Safety and Effects of EMD 72000 in Subjects With Recurrent Ovarian Cancer","source_id_and_acronym":"NCT00073541 - EMD 72000-030","lead_sponsor":"EMD Serono","biomarkers":" EGFR","pipe":" | ","alterations":" EGFR expression","tags":["EGFR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EGFR expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e matuzumab (EMD 72000)"],"overall_status":"Completed","enrollment":" Enrollment 38","initiation":"Initiation: 04/01/2003","start_date":" 04/01/2003","primary_txt":" Primary completion: 03/01/2004","primary_completion_date":" 03/01/2004","study_txt":" Completion: 08/01/2004","study_completion_date":" 08/01/2004","last_update_posted":"2017-01-20"}]